Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease

Journal of Paediatrics and Child Health

Volumn 48, Issue 5, 2012, Pages 395-401

  Alexander, Peta M A ^a   Eastaugh, Lucas ^a   Royle, Jenny ^c   Daley, Andrew J ^b   Shekerdemian, Lara S ^a,d   Penny, Daniel J ^a,d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b Department of Microbiology ^*  (Australia)

^c Department of General Medicine   (Australia)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

bronchiolitis; congenital heart disease; palivizumab; respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; ASSISTED VENTILATION; CONTROLLED STUDY; DISEASE COURSE; HEART DISEASE; HEART HEMODYNAMICS; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INFANT; INTENSIVE CARE; MAJOR CLINICAL STUDY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRAL BRONCHIOLITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; HEART DEFECTS, CONGENITAL; HOSPITALIZATION; HUMANS; HYPERTENSION, PULMONARY; INFANT; INTENSIVE CARE; LENGTH OF STAY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VICTORIA;

EID: 84861184497     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2011.02219.x     Document Type: Article

References (25)

1. Hall CB, Weinberg GA, Iwane MK, et al,. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 2009; 360: 588-98.
2. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA,. Respiratory syncytial viral infection in infants with congenital heart disease. N. Engl. J. Med. 1982; 307: 397-400. (Pubitemid 12089293)
3. Thorburn K,. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch. Dis. Child. 2009; 94: 99-103.
4. Lanari M, Rossi GA, Merolla R, di Luzio Paparatti U,. High risk of nosocomial-acquired RSV infection in children with congenital heart disease. J. Pediatr. 2004; 145: 140.
5. Khongphatthanayothin A, Wong PC, Samara Y, et al,. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit. Care Med. 1999; 27: 1974-81. (Pubitemid 29455133)
6. Feltes TF, Cabalka AK, Meissner HC, et al,. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 2003; 143: 532-40. (Pubitemid 37352516)
7. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112: 1442-6.
8. Tulloh R, Marsh M, Blackburn M, et al,. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol. Young 2003; 13: 420-3. (Pubitemid 41630963)
9. National Advisory Committee on Immunization. Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab). Can. Commun. Dis. Rep. 2003; 29: 1-15.
10. Schmaltz AA,. Stellungnahme der Deutschen Gesellschaft fur Padiatrische Kardiologie zur RSV-Prophylaxe mit Palivizumab (Synagis®). [Article in German]. Monatsschr. Kinderheilkd. 2004; 152: 222-3.
11. Chantepie A, bureau de la Filiale de Cardiologie Pediatrique de la Societe Francaise de Cardiologie. [Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society.] Arch. Pediatr. 2004; 11: 1402-5 (in French). (Pubitemid 39446428)
12. Figueras Aloy J, Quero J, Doménech E, et al,. Comité de Estándares de la Sociedad Española de Neonatología. [Recommendations for the prevention of respiratory syncytial virus infection.] An. Pediatr. (Barc.) 2005; 63: 357-62 (in Spanish). (Pubitemid 41695929)
13. Nakazawa M, Saji T, Ichida F, Oyama K, Harada K, Kusuda S,. Guidelines for the use of palivizumab in infants and young children with congenital heart disease. Pediatr. Int. 2006; 48: 190-3.
14. Tulloh RM, Feltes TF,. The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease. Cardiol. Young 2005; 15: 274-8. (Pubitemid 41388054)
15. Australian Drug Evaluation Committee (ADEC) 231st meeting recommendations of the Therapeutic Goods Administration. Commonwealth of Australia Gazette 2004; No GN 1 7 January 2004.
16. World Health Organization WHO Policy Statement. The Use of Opened Multi-Dose Vials of Vaccine in Subsequent Immunization Sessions, 2000. Available from: [accessed 10 October 2011].
17. Alexander R, Lamb D, White D, et al,. 'RETCIF': a rapid, sensitive method for detection of viruses, applicable for large numbers of clinical samples. J. Virol. Methods 2001; 97: 77-85. (Pubitemid 32718743)
18. Freymuth F, Vabret A, Cuvillon-Nimal D, et al,. Comparison of multiplex PCR assays and conventional techniques for the diagnostic of respiratory virus infections in children admitted to hospital with an acute respiratory illness. J. Med. Virol. 2006; 78: 1498-504. (Pubitemid 44533882)
19. Riley M, Halliday J,. Birth defects in Victoria 2005-2006. Victorian Perinatal Data Collection Unit. Melbourne: Victorian Government Department of Human Services, 2008
20. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J. Perinatol. 2008; 28: 511-7. (Pubitemid 351973995)
21. Geskey JM, Thomas NJ, Brummel GL,. Palivizumab in congenital heart disease: should international guidelines be revised? Expert Opin. Biol. Ther. 2007; 7: 1615-20. (Pubitemid 350161648)
22. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr. Infect. Dis. J. 2003; 22: 823-7. (Pubitemid 37153079)
23. Cohen SA, Zanni R, Cohen A, Harrington M, VanVeldhuisen P, Boron ML, Palivizumab Outcomes Registry Group. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr. Cardiol. 2008; 29: 382-7. (Pubitemid 351414851)
24. Gooding J, Millage A, Rye AK, Lacroix R,. The cost and safety of multidose use of palivizumab vials. Clin. Pediatr. (Phila.) 2008; 47: 160-3. (Pubitemid 351208299)
25. Dede A, Isaacs D, Torzillo PJ, et al,. Respiratory syncytial virus infections in Central Australia. J. Paediatr. Child Health 2010; 46: 35-9.